638352-78-0

Basic information

• Product Name: 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE
• Synonyms: 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE;2-(2,5-Dimethyl-1H-pyrrol-1-yl)-5-methoxypyridine;2-(2,5-Dimethyl-pyrrol-1-yl)-5-methoxy-pyridine
• CAS NO: 638352-78-0
• Molecular Formula: C₁₂H₁₄N₂O
• Molecular Weight: 202.25
• Mol File: 638352-78-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 337.7°C at 760 mmHg
• Flash Point: 158°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 0.000202mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE(638352-78-0)
• EPA Substance Registry System: 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE(638352-78-0)

Safety Data

• Hazardous Substances Data: 638352-78-0(Hazardous Substances Data)

Usage

Description

5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE is a pyridine derivative with the molecular formula C14H17N3O, featuring a methoxy group and a dimethylpyrrole group. It is a chemical compound that is frequently utilized in organic synthesis and pharmaceutical research.
Used in Pharmaceutical Research:
5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE is used as a chemical intermediate for the development of new drugs, given its unique structure and potential reactivity in various chemical reactions.
Used in Organic Synthesis:
In the field of organic synthesis, 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE is used as a versatile building block, enabling the creation of a wide range of complex organic molecules for various applications.
Used in Biological Systems Study:
5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE may also be used as a research tool in the study of biological systems, potentially aiding in the understanding of molecular interactions and mechanisms within living organisms.
While the exact properties and uses of 5-METHOXY-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)PYRIDINE are still under investigation, its potential applications in drug development and organic synthesis highlight its importance in the fields of chemistry and medicine.

InChI:InChI=1/C12H14N2O/c1-9-4-5-10(2)14(9)12-7-6-11(15-3)8-13-12/h4-8H,1-3H3

Upstream product

• 124-41-4 sodium methylate 
• 477889-91-1 1-(5-iodopyridin-2-yl)-2,5-dimethyl-1H-pyrrole 
• 67-56-1 methanol 
• 228710-82-5 5-bromo-2-(2,5-dimethyl-pyrrol-1-yl)-pyridine 
• 110-13-4 2,5-hexanedione 

Downstream Products

• 10167-97-2 2-amino-5-methoxypyridine 
• 139585-48-1 2-chloro-5-methoxypyridine 
• 1936529-65-5 3-(2-chloro-6-methylphenyl)-7-(2-methoxy-4-(1-methylpiperidin-4-yl)phenylamino)-1-(5-methoxypyridin-2-yl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one 

Relevant articles and documents

BICYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES

HIV inhibitory compounds of formula (I) salts, hydrates, solvates, N-oxides, or stereoisomers thereof, wherein A forms pyridine, pyrimidine, pyrazine, pyridazine, triazine, imidazole, pyrazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, and thiadiazole; R1 is halo, cyano, nitro, C1-6alkyl, polyhaloC1-6alkyl, -C1-6alkyl-OR4, -C(=O)-R5, -C(=O)-OR4, -C(=O)-NR6R7, -OR4, -O-C(=O)-C1-6alkyl, -O-C1-6alkyl-OR4, -O-C1-6alkyl-NR6R7, -O-C1-6alkyl-O-C(=O)-C1-6Alkyl, -O-C1-6alkyl-C(=O)-OR4, -O-C1-6alkyl-C(=O)-NR6R7, -NR6R7, -NR8-C(=O)-R5, -NR8-C(=O)-OR4, -NR8-C(=O)-NR6R7, -NR8-C(=O)-C1-6lkyl-C(=O)-OR4, -NR8-C1-6alkyl-OR4, -NR8-C1-6alkyl-NR6R7, -NR8-C1-6alkyl-imidazo lyl, -NR8-SO2R9, -N=CH-NR6R7, -NH-C(=NH)-NH2, -SO2NR6R7, and -O-PO(OR8)2; D forms pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, imidazole, pyrazole, furane, oxazole, isoxazole, thiophene, thiazole, and isothiazole; R2 is C1-6alkyl, polyhaloC1-6alkyl, halo, cyano, -COOR4, -OR4, and -NR6R7; R3 is phenyl, pyridyl, pyrimidinyl, imidazopyridyl, pyrazolopyridyl, triazolopyridyl, quinoline, imidazopyrimidinyl, pyrazolopyrimidinyl, triazolopyrimidinyl, pyridopyrimidinyl; which may optionally be substituted; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; 25 pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.